Unifiram: general
Unifiram is a novel cognition enhancer strictly related to piracetam-like compounds[1]. In mice and rats, it ameliorates memory impairment at doses about 1,000 times lower than the most active available nootropic compounds[1], and it blocked amnesia caused by several different disruptions to neurotransmission[2]. In binding studies it showed no affinity for the major central receptors or channels tested, meaning its mechanism isn't explained by the usual targets[2]. Potency comparisons to piracetam are contested: some estimates put it at four orders of magnitude more potent[2], others at around 30,000 times[3]. These are animal-study figures, not evidence about effects or safety in people.
That's the core problem: as of 2015, no formal human studies of unifiram have been conducted[3][4], and there is no human or long-term toxicity data at all[3]. Nothing is known about what doses do in a person, how long effects last, or what happens with repeated use. None of that gap is filled by the animal work above — it answers a different question.
Despite this, unifiram is not patented[3][4] and is commonly sold online[3][4].
The compound has two enantiomers. The (R)-(+)-form is more potent than the (S)-(-)-form, producing comparable effects at roughly 3- to 10-fold lower doses[5].
If you're going to use this anyway: there is no reliable human data to calibrate against, so start far lower than animal-potency comparisons might suggest, don't use alone, and don't combine it with anything else.
Formula: C13H15FN2O3S. FDA UNII: N4024LN29G[6].
References
- The novel nootropic compound DM232 (UNIFIRAM) ameliorates memory impairment in mice and rats — University of Florence / Wiley-Liss
- Pharmacological Characterization of DM232 (Unifiram) and DM235 (Sunifiram), New Potent Cognition Enhancers — PMC / Wiley
- Unifi nootropics from the lab to the web: a story of academic (and industrial) shortcomings — Taylor & Francis / Journal of Enzyme Inhibition and Medicinal Chemistry
- Unifiram — Wikipedia
- Enantioselective synthesis and preliminary pharmacological evaluation of the enantiomers of unifiram (DM232), a potent cognition-enhancing agent — PubMed / Wiley
- UNII - N4024LN29G — FDA Global Substance Registration System
Comments
Sign in to join the conversation.
No comments yet.